Fresenius SE & Co. KGaA FRE

Waltz Health®, an EVERSANA® company developing technologies and services that support better-informed decisions on prescription care and Fresenius Kabi®, an operating company of Fresenius, and a leading provider of essential medicines and medical technologies, today announced an agreement to provide employers, payers and pharmacy benefit managers (PBMs) with direct access to three competitively priced biosimilars.

mAbxience, a majority-owned company of Fresenius SE & Co. KGaA (XETR: FRE) (OTCM: FSNUY) with partial ownership from Insud Pharma; and Sandoz (SIX: SDZ) (OTCQX: SDZNY), the global leader in affordable medicines, today announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The collaboration agreement combines mAbxience's proven development and manufacturing capabilities with Sandoz's global commercial reach, creating a pathway to